CD274 and neoplasm: Further, a recent retrospective analysis of RATIONALE-306 also found that tislelizumab + CT was associated with a clinically meaningful improvement in OS compared with placebo + CT among patients with advanced or metastatic, unresectable ESCC and tumor PD-L1 ≥1 at primary analysis (22).